AgomAb Therapeutics NV SEC Filings

Agomab Therapeutics reported full-year 2025 results and confirmed its 2026 outlook, highlighting a strengthened balance sheet and advancing clinical pipeline. The company ended 2025 with cash and cash investments of €116.5 million and subsequently raised $208 million in gross proceeds from its February 2026 IPO, which it expects will fund operations into the first half of 2029.

In 2025 Agomab recorded a consolidated operating loss of €59.3 million and a net loss of €62.5 million, driven mainly by €48.9 million in research and development spending as it progressed ontunisertib for fibrostenosing Crohn’s disease and AGMB-447 for idiopathic pulmonary fibrosis. The company plans to start a Phase 2b study in FSCD and a Phase 2 IPF study in the second half of 2026, with key data readouts from ongoing studies also expected in that period.

The 6-K also furnishes materials for the May 26, 2026 annual general meeting, including financial statements, board and auditor reports, proposed director reappointments and auditor fee adjustments, and confirms that the 2025 statutory accounts are prepared on a going concern basis.

AgomAb Therapeutics, a clinical-stage biopharmaceutical company, reports continued operating losses as it advances fibrotic-disease drug candidates. The company recorded total comprehensive losses of €62.5 million in 2025 and €46.4 million in 2024, mainly from research, development and administrative costs.

As of December 31, 2025, AgomAb held €116.5 million in cash, cash equivalents and cash investments and expects this to fund operations into the first half of 2029. The 20-F highlights 34,167,168 common shares outstanding, IFRS-based financials, extensive risk factors, and reliance on future capital raises and regulatory success for ontunisertib, AGMB-447 and earlier-stage programs.

Agomab Therapeutics reports that Pontifax-related reporting persons beneficially own 3,305,846 common shares representing 6.8% of the class as of 03/31/2026. The filing is a joint Schedule 13G showing shared voting and dispositive power over those shares and includes a Joint Filing Agreement dated April 16, 2026.

The ownership block consists of four Pontifax entities with shared control through Pontifax VI G.P. L.P. and Pontifax Management; Messrs. Tomer Kariv and Ran Nussbaum disclaim beneficial ownership of the underlying entity holdings per the filing.

Agomab Therapeutics NV director David R. Epstein filed an initial ownership report showing stock options over common shares. He holds options covering 770,671 shares at an exercise price of $2.8100 expiring on July 8, 2034, 217,295 shares at $5.2600 expiring on November 4, 2034, and 38,843 shares at $14.2600 expiring on January 15, 2036. Footnotes describe multi-year vesting schedules and note that common shares may be represented by American Depositary Shares on a one-for-one basis.

Agomab Therapeutics NV director and Chief Executive Officer Tim Jasper Knotnerus filed an initial ownership report showing his equity position in the company. The filing lists multiple stock options to buy common shares with exercise prices of $1.1300, $0.0005 and $14.2600, expiring between 2029 and 2036. Some options are fully vested and exercisable, while others vest over time based on continued service. He also reports holding 10,823 common shares directly and 34,394 common shares indirectly through TJK Life Sciences B.V., over which he has voting and dispositive power but disclaims beneficial ownership except for any pecuniary interest.

Agomab Therapeutics NV director Colin Michael Bond filed an initial Form 3 showing holdings of stock options over common shares. He holds options over 96,321 shares with a $3.1800 exercise price and 27,165 shares at $5.2600, both expiring on November 4, 2034, plus 27,921 shares at $14.2600 expiring on January 15, 2036. Footnotes explain that portions of these options vest over time, subject to continued service, that common shares may be represented by American Depositary Shares on a one‑for‑one basis, and that exercise prices are reported in U.S. dollars based on a stated euro conversion rate.

Agomab Therapeutics NV director Hammer Ohad has reported an initial equity position consisting of stock options. These options allow him to buy up to 27,921 common shares at an exercise price of $14.2600 per share until January 15, 2036.

According to the vesting terms, 33% of the shares underlying this option will vest on February 9, 2027, with the remaining shares vesting in 24 equal monthly installments thereafter, subject to his continued service. The common shares may be represented by American Depositary Shares, each currently representing one common share, and the exercise price reflects conversion from euros to U.S. dollars at a stated exchange rate.

Agomab Therapeutics NV’s Chief Financial Officer Pierre Thadee Victor Kemula reported existing stock option holdings in a Form 3. The filing shows three option awards over 289,005, 102,057 and 191,958 common shares at exercise prices of $2.7600, $3.1800 and $14.2600, expiring between July 8, 2034 and January 15, 2036. Footnotes describe time-based vesting, including one grant where 50% of the underlying shares vested on February 9, 2026 with the balance vesting in 24 monthly installments, and another where 25% vests on February 9, 2027 followed by 36 monthly installments. The options relate to common shares, which may be represented by American Depositary Shares on a one-for-one basis.

Agomab Therapeutics director Angelika Martha Jahreis reported her existing stock option holdings in a Form 3. She holds several options over common shares, including 94,438 shares at an exercise price of $3.10 per share expiring on October 10, 2033. Other options cover 1,884, 27,165 and 31,505 underlying shares with exercise prices from $2.81 to $14.26 and expirations between July 8, 2034 and January 15, 2036. Footnotes state some options are fully vested, while others vest in scheduled monthly installments from February 9, 2026 and February 9, 2027, contingent on continued service.